Within solid tumor targeted therapies, we are focused on discovering and developing transformative treatments for lung cancer, urothelial cancer (bladder cancer) and colorectal cancer.
Lung cancer
We are committed to leading a paradigm shift in the treatment of lung cancer, the second most common cancer in both men and women. Our strategy involves targeting the complex nature of the disease by interfering with multiple disease mechanisms. This involves three distinct approaches: targeted therapy with small and large molecules, bi-specifics designed to affect two different targets, and vaccine-based therapy. Our focus includes non-small cell lung cancer (NSCLC), as well as small cell lung cancer. About 85 percent of lung cancers are NSCLC; the 5-year survival rate for patients diagnosed with NSCLC is 25 percent.
Urothelial cancer (bladder cancer)
Despite available therapies, there is a high unmet need based on the prevalence of poor outcomes. We are focusing on better understanding the drivers of urothelial cancer so that we can leverage targeted therapies alone and in combination to improve outcomes. More than 570,000 new cases were diagnosed in 2020 alone
Colorectal cancer
In colorectal cancer, we are exploring stem cell properties, including how they self-renew, and the related hypothesis that tumors are proliferated by a type of cancer stem cell. We are also pursuing ways to prevent and arrest the development of malignancies of the colon and rectum by diagnosing and treating precursor lesions. Colorectal cancer is the second leading cause of cancer deaths worldwide, with more than 1.9 million cases diagnosed in 2020.